Gain Therapeutics IncNASDAQ:GANXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.6400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4400/ 1
- Ask / Lots1.8800/ 2
- Open / Previous Close--- / 1.6400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GANX |
|---|---|---|
| 09:32 ET | 3438 | 1.81 |
| 09:34 ET | 1140 | 1.78 |
| 09:38 ET | 9586 | 1.76 |
| 09:39 ET | 2497 | 1.7331 |
| 09:41 ET | 1216 | 1.7399 |
| 10:10 ET | 200 | 1.7552 |
| 10:12 ET | 100 | 1.7552 |
| 10:14 ET | 400 | 1.75 |
| 10:15 ET | 1300 | 1.7202 |
| 10:17 ET | 7817 | 1.723 |
| 10:21 ET | 3708 | 1.72 |
| 10:24 ET | 395 | 1.715 |
| 10:28 ET | 2500 | 1.715 |
| 10:39 ET | 15100 | 1.69 |
| 10:42 ET | 6493 | 1.67 |
| 10:44 ET | 37509 | 1.6563 |
| 10:46 ET | 4374 | 1.645 |
| 10:48 ET | 6561 | 1.675 |
| 10:51 ET | 700 | 1.6899 |
| 10:53 ET | 150 | 1.68 |
| 10:55 ET | 500 | 1.681 |
| 11:00 ET | 4232 | 1.67 |
| 11:02 ET | 10050 | 1.65 |
| 11:04 ET | 5653 | 1.6299 |
| 11:06 ET | 3147 | 1.62 |
| 11:08 ET | 13891 | 1.6254 |
| 11:09 ET | 19796 | 1.6 |
| 11:11 ET | 10413 | 1.5937 |
| 11:13 ET | 8274 | 1.5869 |
| 11:15 ET | 4990 | 1.58 |
| 11:18 ET | 5211 | 1.56 |
| 11:20 ET | 10273 | 1.555 |
| 11:24 ET | 27127 | 1.57 |
| 11:26 ET | 4990 | 1.55 |
| 11:27 ET | 4993 | 1.5668 |
| 11:31 ET | 11160 | 1.6184 |
| 11:33 ET | 1300 | 1.63 |
| 11:36 ET | 5000 | 1.6114 |
| 11:44 ET | 100 | 1.619 |
| 11:45 ET | 9500 | 1.61 |
| 11:47 ET | 442 | 1.6009 |
| 11:51 ET | 6732 | 1.6 |
| 11:56 ET | 5406 | 1.56 |
| 11:58 ET | 200 | 1.58 |
| 12:00 ET | 4385 | 1.6 |
| 12:02 ET | 1100 | 1.6181 |
| 12:03 ET | 700 | 1.6106 |
| 12:07 ET | 1400 | 1.6322 |
| 12:18 ET | 100 | 1.625 |
| 12:23 ET | 36975 | 1.6982 |
| 12:25 ET | 1500 | 1.6709 |
| 12:30 ET | 100 | 1.71 |
| 12:34 ET | 800 | 1.68 |
| 12:36 ET | 200 | 1.67 |
| 12:39 ET | 100 | 1.67 |
| 12:43 ET | 400 | 1.67 |
| 12:45 ET | 3200 | 1.65 |
| 12:59 ET | 100 | 1.68 |
| 01:24 ET | 1800 | 1.66 |
| 01:28 ET | 100 | 1.64 |
| 01:39 ET | 200 | 1.62 |
| 01:44 ET | 9000 | 1.6101 |
| 01:57 ET | 400 | 1.632 |
| 02:26 ET | 1000 | 1.65 |
| 02:33 ET | 13100 | 1.665 |
| 02:36 ET | 500 | 1.65 |
| 02:38 ET | 100 | 1.64 |
| 02:40 ET | 2700 | 1.64 |
| 02:44 ET | 4500 | 1.65 |
| 02:51 ET | 400 | 1.6481 |
| 02:54 ET | 600 | 1.65 |
| 02:58 ET | 2385 | 1.65 |
| 03:03 ET | 216 | 1.67 |
| 03:05 ET | 600 | 1.66 |
| 03:07 ET | 367 | 1.64 |
| 03:20 ET | 590 | 1.66 |
| 03:21 ET | 500 | 1.6553 |
| 03:27 ET | 420 | 1.658825 |
| 03:38 ET | 600 | 1.65 |
| 03:41 ET | 3810 | 1.6326 |
| 03:48 ET | 200 | 1.638561 |
| 03:54 ET | 4871 | 1.6301 |
| 03:57 ET | 5960 | 1.64 |
| 03:59 ET | 5599 | 1.64 |
Yesterday
Sep 30, 2024
Sep 26, 2024
Sep 19, 2024
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024, from 7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 3, 2024
DJ Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 7:42AM ET on Tuesday Sep 03, 2024 by Dow Jones
7:42AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gain Therapeutics Inc | 41.9M | -1.2x | --- |
Achilles Therapeutics PLC | 41.1M | -0.6x | --- |
vTv Therapeutics Inc | 40.8M | -2.0x | --- |
Immix Biopharma Inc | 40.6M | -1.8x | --- |
HST Global Inc | 43.2M | -49.8x | --- |
Lantern Pharma Inc | 40.5M | -2.3x | --- |
Company Information
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Contact Information
- Headquarters
- 4800 Hampden Lane, Suite 200BETHESDA, MD, United States 20814
- Phone
- 301-500-1556
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Khalid Islam
- Interim Chief Executive Officer, Chief Financial Officer, Secretary
- Gene Mack
- Director
- Eric Richman
- Independent Director
- Dov Goldstein
- Independent Director
- Hans Hasler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $41.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-1.33 |
Book Value | $0.78 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
